tradingkey.logo
搜尋

Sol Gel Technologies Ltd

SLGL
添加自選
82.250USD
-2.940-3.45%
收盤 07-31 16:00美東報價延遲15分鐘
268.87M總市值
虧損本益比TTM

Sol Gel Technologies Ltd

82.250
-2.940-3.45%

關於 Sol Gel Technologies Ltd 公司

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltd簡介

公司代碼SLGL
公司名稱Sol Gel Technologies Ltd
上市日期Feb 01, 2018
CEO- -
員工數量34
證券類型Ordinary Share
年結日Feb 01
公司地址Golda Meir 7
城市NESS-ZIONA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編- -
電話97289313433
網址http://www.sol-gel.com
公司代碼SLGL
上市日期Feb 01, 2018
CEO- -

Sol Gel Technologies Ltd公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--
Mr. Itai Arkin
Mr. Itai Arkin
Director
Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
1.55K
--
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--

常見問題

Sol Gel Technologies Ltd的前五大股東是誰?

Sol Gel Technologies Ltd的前五大股東如下:Mr. Moshe (Mori) Arkin

有多少機構持有Sol Gel Technologies Ltd(SLGL)的股份?

截至2026Q1,共有39家機構持有Sol Gel Technologies Ltd的股份,合計持有的股份價值約為1.00M,占公司總股份的30.93% 。與2025Q4相比,機構持股有所增加,增幅為-175336.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有